ERBB2 and breast carcinoma: Informed by the results of the PHILA and PHEDRA phase 3 studies, pyrotinib, combined with the anti‐HER2 monoclonal antibody trastuzumab and docetaxel, has gained approval in China for treating HER2‐positive breast cancer in both first‐line and neoadjuvant settings.1, 15